CA3091554A1 — Formulations for reducing hair loss and/or increasing hair regrowth
Assigned to Triple Hair Inc · Expires 2022-02-28 · 4y expired
What this patent protects
The invention relates to formulations comprising 2% to 10% minoxidil, 0.01% to 15% of a prostaglandin analogue, and, optionally 0.01% to 15% finasteride, and to formulations comprising 0.1 to 60% Dapsone and/or 0.1 to 20% Minocycline, tetracycline or doxycycline as an active ingr…
USPTO Abstract
The invention relates to formulations comprising 2% to 10% minoxidil, 0.01% to 15% of a prostaglandin analogue, and, optionally 0.01% to 15% finasteride, and to formulations comprising 0.1 to 60% Dapsone and/or 0.1 to 20% Minocycline, tetracycline or doxycycline as an active ingredient. In one embodiment, the prostaglandin analogue is latanoprost. In a preferred embodiment, the composition comprises 5% minoxidil and 0.03% latanoprost. In another preferred embodiment, the composition further comprises 0.1% finasteride. The invention also relates to the use of the formulations to reduce hair loss and/or increase regrowth of hair in a human subject.
Drugs covered by this patent
- Aveed (TESTOSTERONE UNDECANOATE) · Marius
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.